Ensysce Biosciences reported Q2 2024 financial results and provided updates on its pain and opioid use disorder (OUD) programs. The company's PF614-MPAR, an FDA-designated Breakthrough Therapy, is progressing to a Phase 1b study to verify overdose protection and effective oxycodone delivery. Ensysce also selected PF9001 as the lead candidate for its OUD program.The company is finalizing the Phase 3 protocol for PF614, its lead TAAP™ product for severe pain, with the trial expected to start in H2 2024. Q2 financial results showed $1.0 million in cash as of June 30, 2024. Federal grant funding was $0.2 million, down from $0.5 million YoY. R&D expenses decreased to $0.9 million from $1.6 million YoY, while G&A expenses remained stable at $1.2 million.Net loss attributable to common stockholders for Q2 2024 was $2.0 million, compared to $2.2 million in Q2 2023. Ensysce continues to advance its proprietary TAAP™ and MPAR® platforms to develop safer prescription drugs for pain management and OUD treatment.

Ensysce Biosciences reported Q2 2024 financial results and provided updates on its pain and opioid use disorder (OUD) programs. The company's PF614-MPAR, an FDA-designated Breakthrough Therapy, is progressing to a Phase 1b study to verify overdose protection and effective oxycodone delivery. Ensysce also selected PF9001 as the lead candidate for its OUD program.The company is finalizing the Phase 3 protocol for PF614, its lead TAAP™ product for severe pain, with the trial expected to start in H2 2024. Q2 financial results showed $1.0 million in cash as of June 30, 2024. Federal grant funding was $0.2 million, down from $0.5 million YoY. R&D expenses decreased to $0.9 million from $1.6 million YoY, while G&A expenses remained stable at $1.2 million.Net loss attributable to common stockholders for Q2 2024 was $2.0 million, compared to $2.2 million in Q2 2023. Ensysce continues to advance its proprietary TAAP™ and MPAR® platforms to develop safer prescription drugs for pain management and OUD treatment.